Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Receivables (2020 - 2025)

RxSight's Receivables history spans 6 years, with the latest figure at $23.4 million for Q4 2025.

  • For Q4 2025, Receivables fell 22.19% year-over-year to $23.4 million; the TTM value through Dec 2025 reached $23.4 million, down 22.19%, while the annual FY2025 figure was $23.4 million, 22.19% down from the prior year.
  • Receivables reached $23.4 million in Q4 2025 per RXST's latest filing, down from $24.2 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $31.0 million in Q1 2025 to a low of $3.9 million in Q2 2021.
  • Average Receivables over 5 years is $16.7 million, with a median of $15.2 million recorded in 2023.
  • Peak YoY movement for Receivables: skyrocketed 125.34% in 2022, then fell 22.19% in 2025.
  • A 5-year view of Receivables shows it stood at $4.9 million in 2021, then surged by 125.34% to $11.0 million in 2022, then skyrocketed by 85.11% to $20.3 million in 2023, then skyrocketed by 48.17% to $30.0 million in 2024, then fell by 22.19% to $23.4 million in 2025.
  • Per Business Quant, the three most recent readings for RXST's Receivables are $23.4 million (Q4 2025), $24.2 million (Q3 2025), and $28.1 million (Q2 2025).